Core Insights - Mineralys Therapeutics, Inc. is focused on developing innovative therapies for cardiovascular and renal diseases, addressing unmet medical needs through advanced research and development efforts [1] - The company is competing within the pharmaceutical sector, aiming to bring effective treatments to market and challenge other companies in the same space [1] Financial Performance - On March 13, 2026, a price target of $30 was set for MLYS by Dennis Ding from Jefferies, indicating a potential upside of approximately 14.37% from the trading price of $26.23 at that time [2] - MLYS's Q4 2025 earnings call provided insights into its financial performance and strategic initiatives, highlighting significant developments and plans for growth [3] - Currently, MLYS is priced at $26.19, reflecting a decrease of 2.96% with a drop of $0.80, and has fluctuated between a low of $25.45 and a high of $28.65 during the day [4] - Over the past year, MLYS has experienced significant volatility, reaching a high of $47.65 and a low of $10.44 [4][6] - The company's market capitalization is approximately $1.74 billion, indicating its size and market presence [5] - Today's trading volume for MLYS on NASDAQ is 1,380,806 shares, reflecting active investor interest and engagement [5]